
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): June 16, 2017

TherapeuticsMD, Inc.

(Exact Name of Registrant as Specified in its Charter)

Nevada

(State or Other
Jurisdiction of Incorporation)

001-00100

(Commission File Number)

87-0233535

(IRS Employer
Identification No.)

6800 Broken Sound Parkway NW,
Third Floor
Boca Raton, FL 33487

(Address of Principal Executive Office) (Zip Code)

Registrant's telephone number, including area code: (561) 961-1900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 16, 2017, TherapeuticsMD, Inc. (the “Company”) held its 2017 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company considered and voted on proposals to: (1) elect ten directors, each to serve until the Company’s next annual meeting of stockholders or until their successors are duly elected and qualified, (2) provide a non-binding advisory vote on the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2016, and (3) ratify the appointment of Grant Thornton, LLP, an independent registered public accounting firm, as the independent auditor of the Company for the fiscal year ending December, 31, 2017.

Set forth below are the final voting results for each proposal submitted to a vote of the stockholders at the Annual Meeting. For more information on the following proposals, see the Company’s 2017 Proxy Statement, as filed with the United States Securities and Exchange Commission on April 25, 2017.

Proposal 1: To elect ten directors, each to serve until the Company’s next annual meeting of stockholders or until their successors are duly elected and qualified.

Nominee	For	Against	Abstain	Broker Non-Votes
Tommy G. Thompson	141,261,345	0	11,645,675	31,719,830
Robert G. Finizio	151,780,533	0	1,126,487	31,719,830
John C.K. Milligan, IV	149,402,979	0	3,504,041	31,719,830
Brian Bernick, M.D.	149,414,644	0	3,492,376	31,719,830
J. Martin Carroll	152,215,003	0	692,017	31,719,830
Cooper C. Collins	152,219,353	0	687,667	31,719,830
Robert V. LaPenta, Jr.	152,191,005	0	716,015	31,719,830
Jules A. Musing	148,621,489	0	4,285,531	31,719,830
Angus C. Russell	152,216,997	0	690,023	31,719,830
Nicholas Segal	152,205,414	0	701,606	31,719,830

Proposal 2: To provide a non-binding advisory vote on the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2016.

For	Against	Abstain	Broker Non-Votes
150,902,446	1,784,583	219,991	31,719,830

Proposal 3: To ratify the appointment of Grant Thornton, LLP, an independent registered public accounting firm, as the independent auditor of the Company for the fiscal year ending December 31, 2017.

For	Against	Abstain	Broker Non-Votes
184,022,279	482,210	122,361	0

Each of the director nominees and proposals received the necessary votes in favor to be adopted by the Company’s stockholders at the Annual Meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 19, 2017

THERAPEUTICSMD, INC .

By: /s/ Daniel A. Cartwright

Name: Daniel A. Cartwright

Title: Chief Financial Officer
